Cargando…

A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery

BACKGROUND: Morbidly obese patients with obstructive sleep apnea are extremely sensitive to sedative premedication. Intranasal dexmedetomidine is painless and quick acting. Intranasal dexmedetomidine can be used for premedication as it produces adequate sedation and also obtund hemodynamic response...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayaraman, Lakshmi, Sinha, Aparna, Punhani, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713663/
https://www.ncbi.nlm.nih.gov/pubmed/23878437
http://dx.doi.org/10.4103/0970-9185.111680
_version_ 1782277218823569408
author Jayaraman, Lakshmi
Sinha, Aparna
Punhani, Dinesh
author_facet Jayaraman, Lakshmi
Sinha, Aparna
Punhani, Dinesh
author_sort Jayaraman, Lakshmi
collection PubMed
description BACKGROUND: Morbidly obese patients with obstructive sleep apnea are extremely sensitive to sedative premedication. Intranasal dexmedetomidine is painless and quick acting. Intranasal dexmedetomidine can be used for premedication as it produces adequate sedation and also obtund hemodynamic response to laryngoscopy and tracheal intubation. MATERIALS AND METHODS: Forty morbidly obese patients with BMI > 35 were chosen and divided into two groups. Group DEX received intranasal dexmedetomidine 1 mcg/kg (ideal body weight) while other group (AZ) received oral alprazolam 0.5 mg. Sedation scale, heart rate and the mean arterial pressure was assessed in both the groups at 0 hour, 45 minutes, during laryngoscopy and tracheal intubation. RESULTS: The demographic profile, baseline heart rate, means arterial pressure, oxygen saturation and sedation scale was comparable between the two groups. The sedation scores, after 45 min, were statistically significant between the two groups i.e., 2.40 ± 1.09 in the AZ group as compared to 3.20 ± 1.79 in DEX group P value 0.034. The heart rate, mean arterial pressure and oxygen saturation were statistically similar between the two groups, after 45 min. The heart rate was significantly lower in the DEX group as compared to the AZ group. There was no statistical difference in the mean arterial pressure between the two groups either during laryngoscopy or tracheal intubation. CONCLUSION: Intranasal dexmedetomidine is a better premedication agent in morbidly obese patients than oral alprazolam.
format Online
Article
Text
id pubmed-3713663
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37136632013-07-22 A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery Jayaraman, Lakshmi Sinha, Aparna Punhani, Dinesh J Anaesthesiol Clin Pharmacol Original Article BACKGROUND: Morbidly obese patients with obstructive sleep apnea are extremely sensitive to sedative premedication. Intranasal dexmedetomidine is painless and quick acting. Intranasal dexmedetomidine can be used for premedication as it produces adequate sedation and also obtund hemodynamic response to laryngoscopy and tracheal intubation. MATERIALS AND METHODS: Forty morbidly obese patients with BMI > 35 were chosen and divided into two groups. Group DEX received intranasal dexmedetomidine 1 mcg/kg (ideal body weight) while other group (AZ) received oral alprazolam 0.5 mg. Sedation scale, heart rate and the mean arterial pressure was assessed in both the groups at 0 hour, 45 minutes, during laryngoscopy and tracheal intubation. RESULTS: The demographic profile, baseline heart rate, means arterial pressure, oxygen saturation and sedation scale was comparable between the two groups. The sedation scores, after 45 min, were statistically significant between the two groups i.e., 2.40 ± 1.09 in the AZ group as compared to 3.20 ± 1.79 in DEX group P value 0.034. The heart rate, mean arterial pressure and oxygen saturation were statistically similar between the two groups, after 45 min. The heart rate was significantly lower in the DEX group as compared to the AZ group. There was no statistical difference in the mean arterial pressure between the two groups either during laryngoscopy or tracheal intubation. CONCLUSION: Intranasal dexmedetomidine is a better premedication agent in morbidly obese patients than oral alprazolam. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3713663/ /pubmed/23878437 http://dx.doi.org/10.4103/0970-9185.111680 Text en Copyright: © Journal of Anaesthesiology Clinical Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jayaraman, Lakshmi
Sinha, Aparna
Punhani, Dinesh
A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
title A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
title_full A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
title_fullStr A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
title_full_unstemmed A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
title_short A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
title_sort comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713663/
https://www.ncbi.nlm.nih.gov/pubmed/23878437
http://dx.doi.org/10.4103/0970-9185.111680
work_keys_str_mv AT jayaramanlakshmi acomparativestudytoevaluatetheeffectofintranasaldexmedetomidineversusoralalprazolamasapremedicationagentinmorbidlyobesepatientsundergoingbariatricsurgery
AT sinhaaparna acomparativestudytoevaluatetheeffectofintranasaldexmedetomidineversusoralalprazolamasapremedicationagentinmorbidlyobesepatientsundergoingbariatricsurgery
AT punhanidinesh acomparativestudytoevaluatetheeffectofintranasaldexmedetomidineversusoralalprazolamasapremedicationagentinmorbidlyobesepatientsundergoingbariatricsurgery
AT jayaramanlakshmi comparativestudytoevaluatetheeffectofintranasaldexmedetomidineversusoralalprazolamasapremedicationagentinmorbidlyobesepatientsundergoingbariatricsurgery
AT sinhaaparna comparativestudytoevaluatetheeffectofintranasaldexmedetomidineversusoralalprazolamasapremedicationagentinmorbidlyobesepatientsundergoingbariatricsurgery
AT punhanidinesh comparativestudytoevaluatetheeffectofintranasaldexmedetomidineversusoralalprazolamasapremedicationagentinmorbidlyobesepatientsundergoingbariatricsurgery